Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | CDC7 | O00311 | 4/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.45 |
| ▸ | PIM1 | P11309 | 3/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | PRKACA | P17612 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 3/20 | 0.44 |
| ▸ | CASP7 | P55210 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21948058 | 0.93 | KDM4E (0.47) | KDM4EHPGDHSD17B10ALDH1A1NPC1 | |
| SCHEMBL21964836 | 0.91 | CDC7 (0.49) | CDC7CDK2PIM1ROCK2PRKACA | |
| SCHEMBL21961843 | 0.90 | KDM4E (0.47) | KDM4EHPGDHSD17B10ALDH1A1NPC1 | |
| SCHEMBL20689484 | 0.89 | KDM4E (0.45) | KDM4EHPGDHSD17B10ALDH1A1NPC1 | |
| SCHEMBL20689336 | 0.89 | KDM4E (0.45) | KDM4EHPGDHSD17B10ALDH1A1NPC1 | |
| SCHEMBL21948982 | 0.89 | CDC7 (0.49) | CDC7CDK2PIM1ROCK2PRKACA | |
| SCHEMBL21961725 | 0.89 | KDM4E (0.49) | KDM4EHPGDHSD17B10ALDH1A1NPC1 | |
| SCHEMBL21948920 | 0.88 | KDM4E (0.45) | KDM4EHPGDHSD17B10ALDH1A1NPC1 | |
| SCHEMBL21947290 | 0.86 | KDM4E (0.48) | KDM4EHPGDHSD17B10ALDH1A1NPC1 | |
| SCHEMBL21960682 | 0.85 | CDC7 (0.49) | KDM4EHPGDHSD17B10ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221453-B2 | Substituted pyrazolo[5′,1′:2,3]pyrimido[5,4-b][1,4]oxazines as TYK2 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-11 | — | — | US | disclosed |
| US-20230110996-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS TYK2 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-04-13 | — | — | US | disclosed |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-11414431-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors | NIMBUS LAKSHMI, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| WO-2020081508-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020081508-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-15 | — | — | US | disclosed |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| WO-2019023468-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885HPGD 4476/4885HSD17B10 2692/4885 |
| US-20230110996-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS TYK2 INHIBITORS | TYK2, JAK1, MATK | KDM4E 519/4885HPGD 4096/4885HSD17B10 3979/4885 |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KDM4E 391/4885HPGD 4476/4885HSD17B10 2692/4885 |
| US-11414431-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors | TYK2, JAK1, JAK2 | KDM4E 530/4885HPGD 4016/4885HSD17B10 3527/4885 |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885HPGD 4476/4885HSD17B10 2692/4885 |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885HPGD 4476/4885HSD17B10 2692/4885 |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885HPGD 4476/4885HSD17B10 2692/4885 |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KDM4E 391/4885HPGD 4476/4885HSD17B10 2692/4885 |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885HPGD 4476/4885HSD17B10 2692/4885 |
| US-12221453-B2 | Substituted pyrazolo[5′,1′:2,3]pyrimido[5,4-b][1,4]oxazines as TYK2 inhibitors | TYK2, JAK1, JAK2 | KDM4E 467/4885HPGD 4015/4885HSD17B10 2476/4885 |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885HPGD 4476/4885HSD17B10 2692/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885HPGD 4476/4885HSD17B10 2692/4885 |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KDM4E 391/4885HPGD 4476/4885HSD17B10 2692/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KDM4E 391/4885HPGD 4476/4885HSD17B10 2692/4885 |
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885HPGD 4476/4885HSD17B10 2692/4885 |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KDM4E 391/4885HPGD 4476/4885HSD17B10 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.